Teladoc Stock Price Target

The firm currently has an overweight rating on the health services provider s stock.

Teladoc stock price target. 30 2020 at 8 07 a m. The high price target for tdoc is 282 00 and the low price target for tdoc is 80 00. Tdoc stock quote history news and other vital information to help you with your stock trading and investing. According to analysts consensus price target of 198 67 teladoc health has a potential upside of 6 3 from its current price of 186 95.

Teladoc health get report share price targets were increased by analysts who saw strong potential in the telehealth services company. The average price target is 0 00 with a high estimate of 0 00. Barron s reported on 07 30 20 that teladoc stock rallies on surging growth amid covid 19 pandemic. 28 wall street analysts have issued ratings and price targets for teladoc health in the last 12 months.

Teladoc health nyse tdoc had its target price increased by stifel nicolaus from 144 00 to 205 00 in a report published on thursday morning benzingaratingstable reports. Their average twelve month price target is 198 67 suggesting that the stock has a possible upside of 7 34. Common stock tdoc. Teladoc stock price target raised to 238 from 184 at deutsche bank jul.

Et by tomi kilgore teladoc health sets 18 5 billion acquisition. Teladoc health nyse tdoc had its price target lifted by equities researchers at piper sandler from 220 00 to 232 00 in a research note issued to investors on thursday the fly reports. Piper sandler s target price would suggest a potential upside of 1 99 from. Based on analysts offering 12 month price targets for tdoc in the last 3 months.

A number of other brokerages have also recently weighed in on tdoc. Nyse tdoc went up by 5 18 from its latest closing price when compared to the 1 year high value of 240 00 and move up 3 78 while tdoc stocks collected 17 27 of gains with the last five trading sessions. Suntrust banks upped their price objective. Teladoc health has been the subject of 16 research reports in the past 90 days demonstrating strong analyst interest in this stock.

But others warned of growing competition.